Apparently all that manufacturing for anticipated new scripts is more than expected, TD. Pfizer may be a little late, but it would appear it really believes in Exubera:
>>Nektar ups Exubera inhaled insulin revenue view
Thu Jul 20, 2006 10:05 AM ET
CHICAGO, July 20 (Reuters) - Nektar Therapeutics (NKTR.O: Quote, Profile, Research) on Thursday raised its revenue outlook for Exubera, the first-ever inhaled insulin product it co-developed with Pfizer Inc (PFE.N: Quote, Profile, Research) .
Nektar, which makes the inhaler used to deliver the diabetes treatment, raised its revenue outlook for Exubera manufacturing and royalty revenue to a range of $70 million to $90 million, from its prior range of $60 million to $80 million.
Nektar said most of the revenue would be generated by manufacturing sales to Pfizer. Pfizer earlier on Wednesday said Exubera would be available across the United States beginning in September. Pfizer will begin a national training and education program for the product this month.
Nektar said it will provide a full-year revenue and net loss outlook for 2006 when it announces its second-quarter results.<<
Cheers, Tuck |
